Finally, treatment of INSS stage 4 NB patients with murine anti-GD2 monoclonal antibody 3F8, GM-CSF, and retinoic acid improved progression-free survival (PFS) by 18% and increased overall survival (OS) by 32% compared to the administration of the 3F8 antibody alone [65]. The gene discussed is CSF2; the disease is neuroblastoma.